Abstract
Introduction: We have previously described modification of Ti that renders the implant surface bactericidal and prevents bacterial colonization in vitro. This study evaluates the efficacy of the same surface in preventing periprosthetic infection in a small mammal model.
Methods: Control or VancTi rods were incubated with S. aureus (Ci=104CFU/mL) in TSB containing 0, 5×10-3, 4, or 100 μg/mL vancomycin at 37°C for 24h. Bacteria were detected by fluorescence (Live/Dead BacLight) and imaged by confocal microscopy. Resistance was tested by incubating control or VancTi rods with S. aureus for 0–8 weeks. Adherent bacteria were tested every 7 days on vancomycin screening agar (6μg/mL).
Results: Using a percutanous approach, the intercondylar region of the knee in rats were identified. The intrameduallry canal of the femur was retrograde reamed using an 18-gauge needle. Infection was induced by injection of 103 CFU S. aureus in 150uL of saline into the femoral canal followed by insertion of a 20 mm Ti implant. Animals were harvested at various time points. At harvest, animals were euthanized with CO2.. Detailed analysis including radiographic, micro-CT, histological, bacteriological, and clinical evaluation was performed.
Results: All animals showed signs of infection within the first few post-operative days with increased soft tissue swelling and limited mobility. At 1 week 75% of the animals showed radiographic signs of periprosthetic infection including periosteal reaction, abscess formation, widened canal, bone destruction, and formation of involucrum. PPI could be prevented in 92% of cases when modified Ti-Van was used. In one animal despite the use of antibiotic-tethered implant, PPI occurred partially due to the pin insertion penetrating the bone cortex.
Discussion: Biologically modified implants with bactericidal surface can have a promising role in management of periprosthetic infection. The modified implant described herein contains a nanoscale surface of covalently linked antibiotics that can potentially confer bactericidal properties throughout the life of the implant
Correspondence should be addressed to Ms Larissa Welti, Scientific Secretary, EFORT Central Office, Technoparkstrasse 1, CH-8005 Zürich, Switzerland
